跳至主要内容
临床试验/EUCTR2015-004613-24-BE
EUCTR2015-004613-24-BE进行中(未招募)1 期

Hit hard and early. The effect of high dose methylprednisolon on nailfold capillary changes and biomarkers in early SSc: a 12-week randomized explorative double-blind placebo-controlled trial. - Hit hard and early

Radboudumc0 个研究点目标入组 30 人开始时间: 2019年4月18日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
Radboudumc
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Age = 18 years
  • - Fulfilling VEDOSS criteria:
  • Raynauds' Phenomenon and
  • Positive for disease specific auto antibodies and
  • Systemic sclerosis specific nail fold capillaroscopic findings
  • - Puffy fingers < 3 years duration
  • - Modified Rodnan Skin Score = 0
  • - Written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 30
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range 0

排除标准

  • - Presence of acrosclerosis, acrosteolysis and digital ulcers
  • - Presence of anti-RNA polymerase III auto antibodies
  • - Previous systemic treatment for SSc, namely methotrexate, prednisone (> 14 days in previous 6 months), mofetyl mycophenolate and cyclophosphamide
  • - Clinically significant internal organ involvement: DLCO < 80% predicted, VC < 70% predicted, renal dysfunction with GFR < 60 ml/min, diastolic dysfunction > grade 1 on echocardiography, pulmonary hypertension, weight loss > 10% in the last 6 months with unknown cause
  • - Usage of medication that influences CYP3A4 (eg carbamazepine / fenobarbital / fenytoïne / rifampicine/itraconazol e/ claritromycine / erytromycine / HIV – proteaseinhibitors) and hypersensitivity for methylprednisolone
  • - Contra-indications for methylprednisolone, such as pregnancy, lactation, psychotic or depressive disorder, ulcus duodeni or ventriculi, untreated hypertension (> 160-90 mmHg) or acute infections

研究者

发起方
Radboudumc

相似试验